Livongo priced its shares above their range to raise more than $355m, providing exits to Merck GHI, M12, Humana, Zaffre Investments and Echo Health Ventures.
Livongo Health, a US-based health management technology developer backed by corporates including pharmaceutical firm Merck & Co and care provider Humana, went public yesterday in an initial public offering sized at more than $355m.
The IPO consisted of approximately 12.7 million shares priced at $28 each, signficantly above the $20 to $23 range it had set, with the number of shares also increased from 10.7 million. Livongo’s shares peaked at $45.46 before closing at $38.10 on the Nasdaq Global…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
